- Home
- TLPH vs GLTO Comparison
TLPH vs GLTO Comparison
Compare TLPH & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | GLTO |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 54.5M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TLPH | GLTO |
|---|---|---|
| Price | $1.08 | $32.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 422.0K | 116.9K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14,267.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $2.01 |
| 52 Week High | $1.57 | $38.33 |
Technical Indicators
Market Signals| Indicator | TLPH | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 59.54 |
| Support Level | $1.02 | $24.53 |
| Resistance Level | $1.22 | $38.33 |
| Average True Range (ATR) | 0.09 | 4.00 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 16.67 | 40.01 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.